Perphenazine
Trilafon
First-Generation AntipsychoticGeneric availableTDM data
ACTIONS Perphenazine has actions at all levels of the central nervous system, particularly the hypothalamus. However, the site and mechanism of action of therapeutic effect are not known.
Compare Perphenazine →FDA-Approved Indications
- Schizophrenia
- Severe nausea and vomiting
What Sets This Drug Apart
- Mid-to-high-potency FGA (D2 5.6 nM) positioned between haloperidol and chlorpromazine; studied in CATIE trial as the FGA comparator to SGAs
- CATIE trial showed perphenazine was non-inferior to SGAs on discontinuation rates, renewing interest in FGAs as cost-effective alternatives
- Lower QTc risk than haloperidol and chlorpromazine; moderate EPS profile
- Available in oral and IM formulations; typical dose 4-16 mg/day, lower dose range than most FGAs
Boxed Warning
WARNING Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated wit